New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GSK;NVS;CBST;TEVA;JAZZ;BP;CHK From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>
March 31, 2015
19:38 EDTCHKOn The Fly: After Hours Movers
HIGHER: Dyax (DYAX), up 47.7% following positive results from Phase 1b clinical trial of DX-2930... Voltari (VLTC), up 93.1% after Carl Icahn reports 52.3% stake... Chesapeake Energy (CHK), up 1.6% after chairman Archie Dunham buys 1M shares of common stock. DOWN AFTER EARNINGS: Cytosorbents (CTSO), down 39.4%... UTi Worldwide (UTIW), down 11.8%... Real Goods Solar (RGSE), down 7%... SYNNEX (SNX), down 3.3%. ALSO LOWER: BioCryst Pharmaceuticals (BCRX), down 8.6% following positive results from Dyax Phase 1b clinical trial of DX-2930... Carpenter Technology (CRS), down 6.4% after targeting a $50M inventory reduction by end of fiscal 2015.
17:02 EDTCHKChesapeake chairman Archie Dunham buys 1M shares of common stock
Subscribe for More Information
14:10 EDTTEVATeva deal yields cash, validation to Concert, says Ladenburg
Subscribe for More Information
10:01 EDTTEVAOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:57 EDTTEVAMomenta strength attributed to report of being viewed as takeover target
Subscribe for More Information
09:50 EDTNVSMylan launches generic Exforge tablets in U.S.
Subscribe for More Information
08:32 EDTTEVATeva launches generic Exforge tablets in the U.S.
Subscribe for More Information
07:25 EDTTEVATeva upgraded at Oppenheimer
Subscribe for More Information
07:03 EDTTEVAAntares Pharma announces FDA approval of TEV-TROPIN
Antares Pharma announced that Ferring Pharmaceuticals has received FDA approval of a name change enabling its newly acquired recombinant human growth hormone to be marketed in the U.S. as Zomacton for injection, and the needle-free delivery system to be marketed in the U.S. as ZOMA-Jet. Ferring also received approval from the FDA to market the 10 mg needle-free injector device which, along with certain consumables, is supplied by Antares to Ferring. Ferring purchased the U.S. rights to Zomacton, formerly TEV-TROPIN, and to ZOMA-Jet, formerly Tjet, in December 2014 from Teva Pharmaceutical (TEVA). Ferring developed and has marketed Zomacton outside of the U.S. since 1988 and in 47 countries globally.
06:16 EDTTEVATeva upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
March 30, 2015
17:46 EDTNVSNovartis announces FDA approval for Jadenu
Subscribe for More Information
16:22 EDTTEVAOn The Fly: Closing Wrap
Subscribe for More Information
14:17 EDTTEVATeva Canada announces launch of Bortezomib for Injection
Subscribe for More Information
13:11 EDTTEVATeva made 'bold move' with Auspex deal, says BMO Capital
Subscribe for More Information
12:22 EDTTEVAOn The Fly: Midday Wrap
Subscribe for More Information
11:49 EDTTEVAAuspex downgraded to Market Perform from Outperform at BMO Capital
Subscribe for More Information
10:16 EDTTEVAAuspex Pharmaceuticals downgraded to Neutral from Overweight at Piper Jaffray
Subscribe for More Information
09:27 EDTTEVAOn The Fly: Pre-market Movers
Subscribe for More Information
09:15 EDTTEVATeva does not rule out bigger deal if opportunity arises
Subscribe for More Information
09:02 EDTTEVAMylan slips amid Abbott share sale, Teva deal for Auspex
Subscribe for More Information
08:42 EDTTEVATeva says has capacity for additional acquisitions after Auspex deal
Teva (TEVA) says the Auspex (ASPX) transaction is not subject to shareholder approval. Comments from Teva CFO Eyal Desheh speaking on the Teva/Auspex conference call regarding the companies' transaction announced this morning.
07:24 EDTJAZZStifel to hold a bus tour
BioTrek: 2015 West Coast Healthcare Therapeutics Bus Tour travels throughout San Francisco on March 30-April 1.
07:03 EDTTEVATeva: Auspex deal represents total consideration of $3.2B in enterprise value
Subscribe for More Information
07:01 EDTTEVATeva to acquire Auspex Pharmaceuticals for $101 per share in cash
Subscribe for More Information
07:00 EDTTEVATeva to acquire Auspex Pharmaceuticals for $101 per share in cash
06:56 EDTBPSeadrill Partners receives notice of termination for West Sirius contract
Seadrill Partners (SDLP) has received a notice of termination from BP Exploration & Production (BP) for the contract for the West Sirius which will be effective after having completed the current well and demobilization, which Seadrill Partners estimates to be by early May. Prior to the cancellation notice, the dayrate and term for the West Sirius and West Capricorn contracts were swapped. The West Sirius dayrate was decreased by $40,000 per day and the term was decreased by two years to expire in July 2017 while the dayrate for the West Capricorn was increased by $40,000 per day and the term was extended by two years to expire in July 2019. Amortized payments for the West Capricorn such as mobilization and upgrades will continue on the original schedule ending in July 2017. In accordance with the cancellation provisions in the West Sirius contract, Seadrill Partners will receive payments over the remaining contract term, now expiring in July 2017. As a result of the termination, Seadrill Partners' backlog will decrease by approximately $160 million. After taking into consideration the expected decrease in operational expense while the unit is cold stacked, and the fact that termination fee payments will not be impacted by downtime, Seadrill Partners does not expect a material impact on its cash flow position over the contract period through July 2017.
05:55 EDTTEVATeva may be close to large acquisition, Bloomberg reports
Analysts believe Teva may be close to making a large acquisition that could be announced by September, Bloomberg reports. Teva CEO Erez Vigodman said last month hat the company is shifting to an "inorganic growth" strategy, and CRT Capital analyst Timothy Chaing says that "The closer we get to September, the closer they’re going to get to to the finish line on completing a deal or at least announcing a deal." Reference Link
05:18 EDTNVSNovartis enters multiyear aliance with Aduro Biotech
Subscribe for More Information
March 29, 2015
15:46 EDTGSKGSK reaches agreement with UK on meningitis B vaccine
Subscribe for More Information
March 27, 2015
07:45 EDTTEVAFDA to hold a public meeting
Subscribe for More Information
07:25 EDTTEVATeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
06:37 EDTBPOil retreats after Goldman says attacks won't have much impact, Reuters reports
Subscribe for More Information
06:21 EDTBPShell pulls back on Chinese operations after oil price slump, WSJ says
Subscribe for More Information
06:17 EDTJAZZJazz Pharmaceuticals assumed with a Buy at Citigroup
Price target lowered to $195 from $202.
March 26, 2015
11:13 EDTGSK, NVSBofA/Merrill European pharma analyst holds an analyst/industry conference call
Subscribe for More Information
10:18 EDTNVSHigh option volume stocks
High option volume stocks: BTX ALL FIVE SGYP SWFT RHT IDCC NVS WGO XBI
07:30 EDTTEVA, JAZZDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
06:36 EDTBPOil surges after Saudis attack Yemen rebels, Reuters reports
The price of West Texas Intermediate oil was up about 4% after Saudi Arabia and other countries bombed Iranian-backed rebel forces in Yemen, according to Reuters. OVerseas stocks fell signficantly following the attacks, the news service noted. Publicly traded oil companies include BP (BP), Chevron (CVX), ConocoPhillips (COP), Exxon Mobil (XOM), Royal Dutch Shell (RDS.A) and Total (TOT). Reference Link
March 24, 2015
15:09 EDTCHKChesapeake shares remain richly valued, says Raymond James
Subscribe for More Information
11:05 EDTNVSNovartis granted orphan status for medulloblastoma treatment
Subscribe for More Information
09:22 EDTCHKOn The Fly: Pre-market Movers
Subscribe for More Information
07:45 EDTTEVA, GSKFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
07:36 EDTCHKChesapeake volatility elevated into Icahn's increasing stake to 10.98%
Chesapeake March weekly call option implied volatility is at 48, April is at 44, July is at 47; compared to its 26-week average of 41 according to Track Data, suggesting large price movement into Carl Icahn disclosed an increased stake in the company to 73M shares (10.98%), up from 66M shares (9.98%) in December.
06:22 EDTTEVATeva appointment shows transformative M&A not off table, says Citigroup
Subscribe for More Information
March 23, 2015
19:13 EDTCHKOn The Fly: After Hours Movers
Subscribe for More Information
17:23 EDTCHKCarl Icahn reports 10.98% stake in Chesapeake
Subscribe for More Information
16:35 EDTCHKChesapeake lowers FY15 CapEx view to $3.5B-$4B from $4B-$4.5B
Subscribe for More Information
16:01 EDTTEVAOptions Update; March 23, 2015
iPath S&P 500 VIX Short-Term Futures down 48c to 25.24 Option volume leaders: AAPL TSLA TWTR GILD CELG FB TSLA AMZN TEVA PBR according to Track Data.
12:10 EDTTEVATeva migraine drug data positive for Amgen, says Piper Jaffray
Piper Jaffray said the "positive" trial data Teva (TEVA) reported for its anti-CGRP antibody in migraines is another important validation for the class of drugs that is also being worked on by Amgen (AMGN), Eli Lilly (LLY) and Alder Biopharmaceuticals (ALDR). The firm said it thinks Amgen is one of the leaders in CGRP antibody space and reiterated its Overweight rating and $187 price target on Amgen shares.
09:45 EDTGSK, NVSUBS to hold a field trip
Subscribe for More Information
09:03 EDTNVSLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
08:50 EDTTEVATeva reports TEV-48125 met endpoints in phase 2b study
Subscribe for More Information
07:36 EDTGSKPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
March 22, 2015
17:59 EDTBPOPEC will not take sole responsibility for supporting oil price, Reuters says
Subscribe for More Information
15:17 EDTGSKGSK looks to conclude negotiations with U.K. on vaccine cost, Bloomberg says
Subscribe for More Information
March 20, 2015
12:41 EDTGSKOn The Fly: Midday Wrap
Stocks began the day sharply higher and have continued to tack on gains throughout the morning. The market’s move put the Nasdaq back above 5,000 and the S&P above 2,100. The market is undergoing quadruple witching, which occurs 4 times per year and typically is accompanied by high volume and volatility. ECONOMIC EVENTS: In the U.S., the economic calendar was quiet. The Baker Hughes U.S. rig count, which has been closely watched in recent months amid the protracted slide in oil prices, is expected at 1:00 pm EDT. The count of U.S. rigs stood at 1125 at the end of last week. In Europe, reports indicate German Chancellor Angela Merkel said Greece has agreed to send a list of overhauled reforms to European officials within days. COMPANY NEWS: Shares of Nike (NKE) advanced 4% following its Q3 earnings beat. Credit Suisse raised Nike's price target to $106 following the report, saying Nike's underlying futures growth remains in double-digits and preliminary FY16 guidance suggests management has been effective in managing currency headwinds... The shares of Biogen (BIIB) rallied 8% after the company reported results for an early stage study of its Alzheimer's drug, BIIB-037. The company announced that the three milligram, six milligram, and ten milligram dose versions of its Alzheimer's treatment, aducanumab, had reduced the amount of amyloid plaque in the brains of Alzheimer's patients taking the drug by statistically significant amounts compared with those taking placebos. The cognitive decline of patients taking BIIB-037 was also significantly less than that of patients who were taking placebos, the company reported. MAJOR MOVERS: Among the notable gainers was Prothena (PRTA), which surged 30% after announcing results from a Phase 1 single ascending dose study of its potential treatment of Parkinson's disease. Also higher was Darden Restaurants (DRI), which gained 4% after the owner of the Olive Garden and Long Horn restaurant chains reported earnings that beat expectations. Among the noteworthy losers was China's Youku Tudou (YOKU), which dropped 9% and was downgraded to Sell at Deutsche Bank after the company reported mixed Q4 results. Also lower was Theravance (THRX), which fell 7% after the company and partner GlaxoSmithKline (GSK) announced that an FDA advisory committee voted that the efficacy data for their Breo Ellipta inhaler provides substantial evidence of a clinically meaningful benefit in adults, however it voted against approval for the proposed indication in 12-17 year olds. INDEXES: Near midday, the Dow was up 189.04, or 1.05%, to 18,148.07, the Nasdaq was up 40.24, or 0.81%, to 5,032.62, and the S&P 500 was up 19.54, or 0.94%, to 2,108.81.
12:33 EDTNVSNovartis says CLEAR Phase IIb study met primary endpoint
Novartis announced results from the CLEAR study demonstrating that Cosentyx is significantly superior to Stelara, a widely used biologic, in achieving clear or almost clear skin for psoriasis patients. The detailed findings were presented in a late-breaking research session at the 73rd Annual Meeting of the American Academy of Dermatology in San Francisco, USA. Cosentyx -- at a dose of 300 mg -- is the first and only interleukin-17A inhibitor approved to treat adult patients with moderate-to-severe plaque psoriasis. In this Phase IIIb study, Cosentyx met the primary endpoint of showing superiority to Stelara as assessed by the Psoriasis Area Severity Index 90 response, known as clear to almost clear skin at Week 16. PASI 90 is considered an important measure of treatment success by the European Medicines Agency and an optimal treatment goal for patients. In addition, completely clear skin at Week 16 was achieved by significantly more patients treated with Cosentyx than those receiving Stelara. In addition, Cosentyx demonstrated rapid onset of action and greater efficacy at all time points in the study up to Week 16, with 50% of Cosentyx patients achieving PASI 75 as early as Week 4 compared to Stelara. The CLEAR study follows the pivotal Phase III FIXTURE study, which showed Cosentyx was superior to Enbrel.
10:43 EDTCHKStocks with call strike movement; CHK FCX
Chesapeake (CHK) July 16 call option implied volatility increased 2% to 50, Freeport McMoRan (FCX) August 20 call option implied volatility decreased 6% to 47 according to IVolatility.
09:47 EDTGSKGlaxoSmithKline, Theravance launch Revlar Ellipta in Italy
In a regulatory filing, GlaxoSmithKline (GSK) and Theravance (THRX) announced the launch of Revlar Ellipta in Italy following the recent approval by the Italian regulatory authorities in December 2014. Relvar is a fixed dose combination of the inhaled corticosteroid fluticasone furoate and the long-acting beta2-agonist vilanterol. The components will be administered using the Ellipta, a dry powder inhaler. In Italy, the product is indicated for the regular treatment of asthma in adults and adolescents aged 12 years and older where use of a combination medicinal product is appropriate; and for the symptomatic treatment of adults with Chronic Obstructive Pulmonary Disease with a FEV1<70% predicted normal post-bronchodilator with an exacerbation history despite regular bronchodilator therapy.
07:41 EDTNVSAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
07:19 EDTBPWhite House expected to unveil fracking rules today, WSJ says
Subscribe for More Information
06:37 EDTBPOil prices fall again, Reuters reports
Subscribe for More Information
March 19, 2015
18:14 EDTGSKGlaxoSmithKline, Theravance announce FDA panel outcome on Breo Ellipta
GlaxoSmithKline (GSK) and Theravance (THRX) announced the outcome of the joint meeting of the Pulmonary-Allergy Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the United States FDA regarding the supplemental New Drug Application for Breo Ellipta as a once-daily inhaled treatment for asthma in patients aged 12 years and older. The FDA Advisory Committee voted that the efficacy and safety data for FF/VI 100/25 mcg and 200/25 mcg once daily in asthma support approval in adults 18 years of age and older (16 for, 4 against). The Committee voted that the efficacy data provides substantial evidence of a clinically meaningful benefit in adults (18 for, 2 against) and that the safety in this population has been adequately demonstrated (17 for, 3 against). The Committee voted against approval for the proposed indication in 12-17 year olds (2 for, 18 against). The Committee voted that the efficacy data was not sufficient to demonstrate the benefit (4 for, 16 against) and the safety (1 for, 19 against) has not been adequately demonstrated in this sub-population. The Committee recommended that a large LABA safety trial with FF/VI should be required in adults (13 yes, 7 no) and in 12-17 year olds (17 yes, 2 no and 1 no-vote), similar to the ongoing LABA safety trials being conducted as an FDA Post-Marketing Requirement by each of the manufacturers of LABA containing asthma treatments. FDA Advisory Committees provide non-binding recommendations for consideration by the FDA. Based on these opinions and the data presented, the FDA will make its final decision on approval, which is expected on April 30.
15:55 EDTNVSAmgen injunction bid for Neupogen biosimilar denied, Reuters reports
Subscribe for More Information
15:13 EDTNVSAmgen denied preliminary injunction for biologics against Novartis, Reuters says
15:12 EDTGSKFDA panel says Breo lacks efficacy data in children with asthma, Bloomberg says
Subscribe for More Information
10:02 EDTCHKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:20 EDTCHKOn The Fly: Pre-market Movers
Subscribe for More Information
08:24 EDTCHKChesapeake downgraded at Sterne Agee
Subscribe for More Information
07:26 EDTGSKFDA to hold a joint advisory committee meeting
The Pulmonary-Allergy Drugs Advisory Committee and the Drug Safety & Risk Management Advisory Committee discuss the supplemental New Drug Application (sNDA) 204275-S001, for fluticasone furoate and vilanterol dry powder for inhalation (with the brand name of BREO® ELLIPTA®), sponsored by Glaxo Group Limited (d/b/a GSK) for the once-daily treatment for asthma in patients aged 12 years and older in a meeting being held in Gaithersburg, Maryland on March 19 at 8 am. Webcast Link
07:19 EDTBPKuwaiti minister says OPEC can't cut oil production, Bloomberg reports
Subscribe for More Information
07:10 EDTGSKTheravance announces trading in common stock halted as FDA meets on sNDA
Subscribe for More Information
06:20 EDTCHKChesapeake downgraded to Underperform from Neutral at Sterne Agee
March 18, 2015
16:13 EDTTEVAFibrocell Science appoints Keith Goldan as CFO
Fibrocell Science announced the appointment of Keith Goldan as senior VP and Chief Financial Officer, effective immediately. Prior to joining Fibrocell, Goldan served as CFO of two publicly traded companies. Most recently he served as SVP and CFO of NuPathe, which was acquired by Teva Pharmaceutical (TEVA) in 2014.
16:00 EDTBPOptions Update; March 18, 2015
iPath S&P 500 VIX Short-Term Futures down 1.20 to 26.10. Option volume leaders: AAPL RAD PBR TWTR FB TSLA CLF BP MGM according to Track Data.
13:05 EDTJAZZJazz Pharmaceuticals management to meet with Piper Jaffray
Subscribe for More Information
11:36 EDTTEVAIgnyta price target raised to $17 from $14 at Leerink
Subscribe for More Information
10:08 EDTTEVAEagle Pharmaceuticals price target increased to $67 from $43 at William Blair
William Blair raised its price target on Eagle Pharmaceuticals to $67 from $43 citing its belief that the company can become profitable and have significant cash flow pending the approval of EP-3102. The company added that it view last week's FDA label change for Teva's (TEVA) Treanda as a positive for EP-3102 and that its new price target assumes 2016 launch and "reasonable" penetration for EP-3102.
10:03 EDTBPBP call activity attributed to renewed takeover speculation
Subscribe for More Information
09:56 EDTBPRumor: BP strength attributed to takeover speculation
Subscribe for More Information
07:13 EDTTEVATeva volatility elevated, shares near four year high
Subscribe for More Information
07:02 EDTBPExterran nominates five new directors to board
Exterran Holdings (EXH) announced that its Board of Directors has nominated the following individuals for election to the Exterran Holdings Board at the Company’s 2015 Annual Meeting of Stockholders on April 28: Anne-Marie N. Ainsworth – former President and CEO of the general partner of Oiltanking Partners, L.P. (OILT); Frances Powell Hawes – independent financial consultant and former CFO of NCI Building Systems (NCS); James H. Lytal – independent energy consultant and former President of Gulfterra Energy Partners LP; Richard R. Stewart- former President and CEO of GE Aero Energy (GE); and Ieda Gomes Yell – Managing Director of Energix Strategy Ltd. and former President of BP Brazil (BP). “In November 2014, we announced a plan to separate Exterran’s international contract operations, international aftermarket services and global fabrication businesses into an independent, publicly traded company in the second half of 2015,” said Mark Sotir, Executive Chairman of the Board. “Our Board has nominated these additional well qualified director candidates in anticipation of certain of Exterran’s directors resigning from the Board at the time of the separation in order to join the board of directors of the new publicly traded company. We have not yet reached a final determination regarding which directors will remain on Exterran’s Board and which directors will join the board of directors of SpinCo at the time of the separation.”
March 17, 2015
19:42 EDTTEVAOn The Fly: After Hours Movers
Subscribe for More Information
16:03 EDTTEVAIgnyta acquires 4 oncology R&D assets from Teva for 1.5M shares of common stock
Teva (TEVA) and Ignyta (RXDX) announced the acquisition by Ignyta of the worldwide rights and assets relating to four targeted oncology development programs in exchange for 1.5M shares of Ignyta’s common stock. Concurrently, Ignyta has entered into stock purchase agreements with Teva, and selected additional healthcare investors, whereby Teva will purchase a further 1.5 million shares of common Ignyta stock at a price of $10 per share in a registered direct offering. The other investors will purchase an additional 2.7M shares at $10 per share, valuing the total offering at approximately $41.6M. Under the terms of the asset purchase agreement with Teva, Ignyta is acquiring all of Teva’s assets and worldwide rights relating to four oncology development programs in exchange for 1.5M shares of Ignyta’s common stock. Teva has agreed not to sell or otherwise transfer any of these shares until March 17, 2016, and Ignyta is required to register the resale of these shares with the SEC prior to such date. Ignyta also assumed all of Teva’s ongoing obligations under certain contracts relating to the purchased programs, including the agreements under which Teva in-licensed rights to the assets.
12:51 EDTNVSNovartis hit with $100M gender discrimination lawsuit, Reuters reports
A proposed class action lawsuit against Novartis claims the drug maker routinely denied female employees equal pay and promotional opportunities, reports Reuters. The $110M lawsuit filed on Tuesday says Novartis' Alcon Laboratories maintains a "boy's club atmosphere" that is hostile to women and bars them from leadership positions. Reference Link
10:26 EDTTEVAOptions with increasing implied volatility
Subscribe for More Information
10:00 EDTCHKOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:13 EDTCHKChesapeake downgraded to Sell from Neutral at Global Hunter
09:11 EDTBPBP study criticized by Gulf oil spill trustees, Financial Times says
Subscribe for More Information
08:27 EDTBPBP says environmental assessment shows most spill impact of short duration
Subscribe for More Information
07:07 EDTGSKVeeva says selected by GlaxoSmithKline for multichannel CRM
Subscribe for More Information
07:06 EDTGSKVeeva selected by GSK as global multichannel CRM partner
Subscribe for More Information
05:32 EDTNVSIncyte announces Novartis receives EC approval for Jakavi
Incyte (INCY) announced that Novartis (NVS) received approval from the European Commission for Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Under the Incyte-Novartis Collaboration and License Agreement signed in 2009, Novartis received exclusive development and commercialization rights to ruxolitinib outside of the United States for all hematologic and oncologic indications, and sells ruxolitinib under the name Jakavi. Ruxolitinib is marketed by Incyte in the United States as Jakafi. Jakafi is approved by the FDA for treatment of people with polycythemia vera who have had an inadequate response to or are intolerant of hydroxyurea. Jakafi is also indicated for treatment of people with intermediate or high-risk myelofibrosis, or MF, including primary MF, post–polycythemia vera MF, and post–essential thrombocythemia MF.
05:30 EDTNVSNovartis receives EU approval for Jakavi in polycythemia vera
Novartis announced that the European Commission has approved Jakavi for the treatment of adult patients with polycythemia vera, or PV, who are resistant to or intolerant of hydroxyurea. Jakavi is the first targeted treatment approved by the European Commission for these patients. Jakavi is the only JAK 1/2 inhibitor available to treat PV and is also currently approved in more than 80 countries to treat myelofibrosis.
<< 1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use